Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Nasopharyngeal Carcinoma 12Esophageal Neoplasms 9Esophageal Squamous Cell Carcinoma 8Squamous Cell Carcinoma of Head and Neck 7Uterine Cervical Neoplasms 6Pancreatic Neoplasms 4Head and Neck Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Stomach Neoplasms 3Recurrence 2Pancreatic cancer, adult 2Lung Neoplasms 2Diffuse Intrinsic Pontine Glioma 2Uterine Cervical Dysplasia 1Squamous Cell Carcinoma of Anal Canal 1Penile Neoplasms 1Pathologic Complete Response 1Pancreatic Cancer Resectable 1Oropharyngeal Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Meningeal Carcinomatosis 1Locally Advanced Rectal Cancer 1Hypopharyngeal Neoplasms 1HCC 1Glioma 1Glioblastoma 1Esophageal 1Colorectal Neoplasms 1Childhood Brain Stem Neoplasm 1

Interventions

nimotuzumab 1lenvatinib 1atezolizumab 1Sorafenib 1Radiotherapy 1Radiosurgery 1Immune Checkpoint Inhibitors 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × HCC × nimotuzumab × Clear all
NCT06413017 2024-05-14

Nimotuzumab Combined With ICIs for the Treatment of Advanced Liver Cancer After First Line Treatment Failure

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Unknown
30 enrolled

HCC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡